Lung cancer biobank aims to unlock secrets of treatment success
NCT ID NCT03387865
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study is building a large collection of blood, tumor tissue, and fecal samples from 500 people with lung cancer. Researchers will track how patients respond to standard treatments and look for biological clues that predict success or failure. The goal is to better understand lung cancer and eventually improve treatment choices.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this study could help identify biological markers that predict which lung cancer treatments work best for individual patients, leading to more personalized care.
- What could go wrong
- This is an observational biobanking study, not a treatment trial. It will not directly benefit participants and may not yield actionable results for years, if at all.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Hôpital Calmette, CHU
RECRUITINGLille, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a simple CT scan catch lung cancer earlier in kuwait?
- Can a new drug combo revive Immunotherapy's power against resistant tumors?
- Seeing the fight: new imaging tracer may reveal how immune cells attack lung cancer
- Your Tumor's DNA might predict immunotherapy success
- Can a new PET tracer light up hidden cancers?
- Fellow veterans may hold the key to earlier lung cancer detection